Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Pneumonia Testing Market size was valued at USD 688.68 million in 2024 and is projected to exceed USD 1.43 billion by the end of 2037, expanding at over 5.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of pneumonia testing is evaluated at USD 721.19 million.
The growth of the market can be attributed to the rising incidence of pneumonia among the global population. Pneumonia caused 745,280 children to die in 2019, accounting for 14.5% of all pediatric fatalities.
A severe respiratory infection that damages the lungs is termed pneumonia. It is the leading infectious cause of child mortality globally. The little sacs in the lungs called alveoli are stuffed with pus and fluid, when someone with pneumonia inhales, which makes breathing difficult and reduces oxygen intake. Pneumonia can be averted in children, treated with affordable, low-tech medicine, and prevented with streamlined treatments. In 2020, there were 47,601 pneumonia-related fatalities in the U.S. which is equivalent to 14.4 mortalities for every 100,000 people.
Pneumonia Testing Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Cases of COVID-19 – Some people with COVID-19 have pneumonia in both lungs. The condition associated with COVID-19 was formerly known as new-corona virus-associated pneumonia (NCIP). The coronavirus disease 2019 was dubbed COVID-19 by the World Health Organization (WHO). Around the world, there have been 8,385,450 reported cases of coronavirus disease 2019 (COVID-19) pneumonia in 2020, with 450,690 fatalities.
- Increasing Incidence of Hospital-acquired pneumonia (HAP) – HAP refers to pneumonia that appears more than 48 hours after being admitted to the hospital. Each year, hospitals in the U.S. witness up to 350,000 HAP events.
- Growing Geriatric Population – Aged individuals are more inclined to have long-term medical issues including heart disease or chronic obstructive pulmonary disease (COPD), which can raise the risk of pneumonia. By 2050, the global population over 60 is predicted to be close to 23%, and from 2020 to 2050, the number of people 80 or older is projected to treble, reaching 430 million.
- Advancement of POCT and Nucleic Acid Detection tests – The development of POCT (point of care test) and improved nucleic acid detection tests in pneumonia testing systems is another factor contributing to the market’s expansion. POCT is desirable owing to its ease of use, increased user approachability, earlier detection, and equivalent accuracy. Thus, POCT helps to achieve early diagnosis and treatment of epidemics as well as daily epidemic control. For instance, Abbot itself provides more than 1.5 billion POCT devices globally each year.
Challenges
- Widespread Utilization of X-ray to Detect Pneumonia
- High Cost of the Testing Devices
- High Preference of Utilizing Traditional Approach to Identify Pneumonia-Causing Pathogens
Pneumonia Testing Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.9% |
|
Base Year Market Size (2024) |
USD 688.68 million |
|
Forecast Year Market Size (2037) |
USD 1.43 billion |
|
Regional Scope |
|
Pneumonia Testing Segmentation
Application (Hospitals, Diagnostic Laboratories, Home Care)
The global pneumonia testing market is segmented and analyzed for demand and supply by application into hospitals, diagnostic laboratories, home care, and others. Out of these, the hospital segment is anticipated to hold the largest share by the end of 2037 on the back of the increasing number of hospitals and cutting-edge technologies provided by the hospitals. There were around 10,900 hospitals in Colombia, 8240 hospitals in Japan, and 6092 hospitals in the United States in 2020. The rising need for pneumonia testing elevates the number of hospitals grows and leads to the expansion of the segment.
Our in-depth analysis of the global market includes the following segments:
|
By Types |
|
|
By Method |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPneumonia Testing Industry - Regional Synopsis
Regionally, the global pneumonia testing market is studied in five major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa region. Amongst these markets, the pneumonia testing market in North America is projected to hold the largest market share by the end of 2037. The market expansion in this area was fueled by the rising prevalence of pneumonia in the region. The existence of significant market participants in the area as well as expanding development of sophisticated PCR-based technologies for speedier test results, additionally, contribute to the expansion of the market. For instance, around 1,493,500 deaths from pneumonia, influenza, or COVID-19, and over 959,400 deaths from pneumonia alone in the United States in 2022.
Companies Dominating the Pneumonia Testing Landscape
- Abbott
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Quidel Corporation
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- INTEC
- OpGen
- BD (Becton, Dickinson, and Company)
- Meridian Bioscience, Inc.
- Luminex Corporation (DiaSorin S.p.A.)
- F. Hoffmann-La Roche Ltd.
In the News
-
bioMérieux, a global leader in invitro diagnostics, unveils that it has reached an agreement to procure Specific Diagnostics, a privately held American Company that has created a rapid antimicrobial susceptibility test (AST) system that provides phenotypic AST directly from positive blood cultures.
-
A corporation among DiaSorin (FTSE MIB: DIA) and B.R.A.H.M.S. GmbH, a division of Thermo Fisher Scientific, has been formed with the goal of developing and marketing the novel LIAISON B.R.A.H.M.S MR-proADM immunodiagnostic test. The test can assist in the detection of several serious illnesses, including sepsis, septic shock, lower respiratory infections, urinary tract infections, and kidney disease.
Author Credits: Radhika Pawar
- Report ID: 4457
- Published Date: Oct 11, 2024
- Report Format: PDF, PPT
